- Home
- ETON vs ONL Comparison
ETON vs ONL Comparison
Compare ETON & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- ONL
- Stock Information
- Founded
- ETON 2017
- ONL 2021
- Country
- ETON United States
- ONL United States
- Employees
- ETON N/A
- ONL N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- ONL Real Estate Investment Trusts
- Sector
- ETON Health Care
- ONL Real Estate
- Exchange
- ETON Nasdaq
- ONL Nasdaq
- Market Cap
- ETON 199.5M
- ONL 226.6M
- IPO Year
- ETON 2018
- ONL N/A
- Fundamental
- Price
- ETON $12.44
- ONL $3.92
- Analyst Decision
- ETON Strong Buy
- ONL Hold
- Analyst Count
- ETON 2
- ONL 1
- Target Price
- ETON $15.00
- ONL N/A
- AVG Volume (30 Days)
- ETON 242.8K
- ONL 269.8K
- Earning Date
- ETON 11-12-2024
- ONL 11-07-2024
- Dividend Yield
- ETON N/A
- ONL 10.06%
- EPS Growth
- ETON N/A
- ONL N/A
- EPS
- ETON N/A
- ONL N/A
- Revenue
- ETON $34,677,000.00
- ONL $169,644,000.00
- Revenue This Year
- ETON $23.05
- ONL N/A
- Revenue Next Year
- ETON $81.27
- ONL N/A
- P/E Ratio
- ETON N/A
- ONL N/A
- Revenue Growth
- ETON 5.64
- ONL N/A
- 52 Week Low
- ETON $3.03
- ONL $3.01
- 52 Week High
- ETON $13.98
- ONL $6.17
- Technical
- Relative Strength Index (RSI)
- ETON 65.21
- ONL 51.41
- Support Level
- ETON $11.64
- ONL $3.97
- Resistance Level
- ETON $13.01
- ONL $4.11
- Average True Range (ATR)
- ETON 0.76
- ONL 0.09
- MACD
- ETON -0.10
- ONL -0.01
- Stochastic Oscillator
- ETON 50.43
- ONL 26.18
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About ONL Orion Office REIT Inc.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.